165 results
6-K
EX-99.2
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
-CURRENT LIABILITIES
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
COMMITMENTS AND CONTINGENT LIABILITIES … CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 5 – LONG-TERM LOAN
In September 2022, the Company entered into a $40 million loan agreement
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
or allogeneic transplantation in cancer patients. Clinical data has demonstrated the ability of motixafortide to mobilize higher numbers of long-term engrafting
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
Current maturities of long-term loan
Contract liabilities
Accounts payable and accruals:
Trade
Other
Current maturities of lease liabilities
Warrants …
Total current liabilities
NON-CURRENT LIABILITIES
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
COMMITMENTS
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities”, said Philip Serlin, Chief Executive Officer of BioLineRx
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
incorporated by reference herein and the accompanying prospectus.
As of December 31, 2023
Actual
As Adjusted
Non-Current Liabilities:
Warrants
Long-term loan … , except share
data)
Non-Current Liabilities:
Warrants
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
20-F/A
x08n ukjygonn7uit
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
3j3riwd72njxwle
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
F-3
e5hvskoln gm9
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
cj1av2e4o
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
81kl2 3efwoy2
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
bvjmf6tj z90l9p
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
iqji z7kw
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
i6p g5onpumsrw2
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
0uu0jwvpn sbg
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
qt7266rvslvek 9ar7l
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
ucan2 gc5
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
v5c3a3qlj5b6r
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
6de4dow0mfapsvyu
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
o9tcsri5o1qn1
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am